US healthcare funds buy Moberg Pharma's OTC business for $155m

The purchase price represents a 14.1x entry multiple for the investors and is 3.3x the group’s revenues.

It will result in a SEK 500m capital gain for listed business Moberg’s investors, which will receive a distribution of SEK 43-45 per share.

The transaction will enable Moberg to focus additional resources on its MOB-015 pipeline program, according to a statement.

Company
Moberg was founded in 2006 and is headquartered in Stockholm. It develops and markets consumer healthcare products to treat and improve the appearance of damaged skin and nails. The company generated EBITDA of SEK 101.7m from sales of SEK 439m in 2018, according to its interim report.

People
Moberg Pharma - Peter Wolpert (CEO).

Advisers
Equity - Sidley Austin (legal); Roschier (legal).
Company - Sawaya Partners (corporate finance); Hansen Law (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Healthcare
• Nordics
• Sweden